Q32 Bio (QTTB) investor relations material

Executive summary

• Advanced bempikibart as lead candidate in Phase 2 trials for alopecia areata and atopic dermatitis, with promising efficacy and safety; SIGNAL-AA Part B exceeded enrollment targets and topline data expected mid-2026.

• First patient dosed in the open-label extension (OLE) of Part B; Part A OLE completed, with results to be reported alongside Part B topline data.

• FDA granted Fast Track designation for bempikibart in AA.

• Divested ADX-097 asset to Akebia Therapeutics, securing upfront and milestone payments, and retained rights to early-stage complement inhibitor platform.

• Raised over $10 million in a registered direct offering and over $14 million via ATM equity sales, strengthening liquidity.

Financial highlights

• Cash and cash equivalents were $50.8 million as of March 31, 2026, excluding $14.2 million in ATM proceeds received after quarter-end.

• Net loss for Q1 2026 was $7.6 million ($0.54 per share), an improvement from $11.0 million ($0.90 per share) in Q1 2025, driven by lower R&D and G&A expenses.

• Operating expenses decreased to $7.7 million from $12.2 million year-over-year, reflecting reduced spend on clinical programs and headcount.

• Research and development expenses decreased to $3.2 million from $7.1 million year-over-year.

• General and administrative expenses fell to $4.5 million from $5.1 million year-over-year.

Outlook and guidance

• Cash runway expected to extend into the first half of 2028, supported by milestone payments and recent financings.

• Additional capital will be needed to advance programs through regulatory approval and commercialization.

• 36-week topline results from SIGNAL-AA Part B anticipated mid-2026; pivotal trial advancement contingent on these results.